Anemia, Sickle Cell
Conditions
Brief summary
Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis
Detailed description
Patients who are experiencing a vaso-occlusive crisis will report to the clinic for treatment and screening into the SGSC-005 study. Patients who meet all inclusion/exclusion criteria will be randomized to receive either SANGUINATE 320 mg/kg or placebo (saline) over a 2 hour infusion period. Assessments of vital signs, ECGs, safety labs, adverse events as well as patient and physician questionnaires will be completed up to 6 hours after the start of the infusion. Patients will then be assessed for discharge either to home or admitted to the hospital for further treatment depending on their disease severity. Follow-up phone calls will be completed 24 hours and 7 days after initiation of treatment . A follow-up visit will be completed in the clinic at 72 hours after initiation of treatment.
Interventions
DRUGSANGUINATE
Single two-hour infusion of SANGUINATE
DRUGPlacebo
Single two-hour infusion of placebo
Sponsors
Prolong Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years, 2. Sickle Cell Disease (all genotypes), 3. Diagnosis of a severe vaso-occlusive crisis (VOC), based on the clinical judgement of the Investigator, 4. Participant needs to be admitted to the ambulatory site for treatment of VOC requiring IV pain medication, 5. Able to provide written consent, 6. Able to receive IV infusion of study drug.
Exclusion criteria
1. In the judgment of the Investigator, the participant is not a good candidate for the study, 2. An acute severe complication of SCD beyond VOC, 3. Pregnant or actively trying to become pregnant, or breastfeeding, 4. Participant had \> 6 urgent visits for SCD complications in the prior 3 months, 5. Fewer than 30 days since any prior treatment with IV pain medication for VOC, 6. Onset of current acute painful crisis \> 3 days prior to dosing, 7. Evidence of moderate to severe renal insufficiency (CrCl \< 50 mL/min) or chronic kidney disease, or of moderate to severe hepatic disease (LFTs \> 2 x ULN) based on past medical history, 8. Concurrent or prior treatment within 90 days with an investigational medication, 9. Abnormal ECG due to cardiac ischemia and/or atrial fibrillation of acute onset, in the opinion of the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to readiness for discharge from ambulatory site | 7 Days | Defined as the time from the start of study drug infusion until the time of participant's response that their pain episode has improved enough for discharge; investigator's assessment of participant's readiness for discharge; and participant no longer requires IV opioid administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of treatment | 1 Day | as determined by changes in vital signs, EKG, biochemical, hematological, and urinalysis measures, and reported AEs |
| Extent of reduction in pain score during ambulatory visit as assessed by the participant on a 10-point pain scale | 1 Day | — |
| Reduction in the rate of hospitalization(s) for VOC after treatment with SANGUINATE and within 7 days post-discharge | 7 Days | — |
| Global assessment of the participant's improvement by the Investigator or study staff (at the time of readiness for discharge from the ambulatory visit, and at the 72-hour follow-up visit) | 7 Days | — |
| Reduction in the rate of recurrent ambulatory visit(s) for the VOC within 7 days post discharge | 7 Days | — |
| Total pain treatment received including the opioid dose (mg/kg) received during ambulatory visit | 1 Day | — |
Countries
United States
Outcome results
None listed